Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications by Mills, Emily M. et al.
REVIEW
Applying switchable Cas9 variants to in vivo gene editing
for therapeutic applications
Emily M. Mills & Victoria L. Barlow & Louis Y. P. Luk &
Yu-Hsuan Tsai
Received: 26 April 2019 /Accepted: 29 July 2019
# The Author(s) 2019
Abstract Progress in targeted gene editing by program-
mable endonucleases has paved the way for their use in
gene therapy. Particularly, Cas9 is an endonuclease with
high activity and flexibility, rendering it an attractive
option for therapeutic applications in clinical settings.
Many disease-causing mutations could potentially be
corrected by this versatile new technology. In addition,
recently developed switchable Cas9 variants, whose
activity can be controlled by an external stimulus, pro-
vide an extra level of spatiotemporal control on gene
editing and are particularly desirable for certain applica-
tions. Here, we discuss the considerations and difficul-
ties for implementing Cas9 to in vivo gene therapy. We
put particular emphasis on how switchable Cas9 vari-
ants may resolve some of these barriers and advance
gene therapy in the clinical setting.
Keywords Endonuclease . Gene therapy. In vivo gene
editing . Switchable Cas9
Gene therapy is a tool to treat or cure diseases by
modifying a patient’s genotype. Modifications include
replacing a lack-of-function gene with its wild-type
sequence, silencing a disease-causing gene that is
constitutively active, or introducing a new gene of novel
function to treat a disease (Dangi et al. 2018; Gupta and
Shukla 2017). Therefore, gene therapy is complementa-
ry to existing therapeutic approaches and provides an
obvious solution to diseases with a clear genetic origin
(Anguela and High 2019). Importantly, gene therapy is
perhaps the only permanent and inheritable solution for
diseases caused by a lack-of-function gene (Cox et al.
2015). Due to its unique advantages, there has been
significant research on its use to tackle otherwise hard-
to-treat diseases, invoking a surge of gene therapies
entering clinical trials (Naldini 2015). Although most
clinical trials rely on ex vivo gene editing, in which cells
are removed from the patient, modified, and then trans-
ferred back, in recent years, more trials are being con-
ducted to explore in vivo gene editing in animal models
(Naldini 2015). The in vivo approach is particularly
beneficial for diseases of the muscles and internal or-
gans, such as Duchenne muscular dystrophy, cystic
fibrosis, and tyrosinemia (Cox et al. 2015; Wang et al.
2017; Mention et al. 2019).
This review limits the discussion to in vivo gene
editing for therapeutic applications. The premise of all
gene editing techniques involves breaking a double-
stranded DNA under the action of an endonuclease
(Fig. 1a), followed by repair via cellular machinery
(Fig. 1b). The mechanism of repair can result in a few
different outcomes. For example, the double-strand
break can be repaired into a new, defined sequence to
correct a diseased gene, or be disrupted to inactivate a
disease-causing gene with autosomal dominant effects.
In comparison to other gene editing systems, the
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clustered regularly interspaced short palindromic re-
peats (CRISPR) system is unique. In particular, CRISPR
associated protein 9 (Cas9) is specifically appealing due
to its high activity and flexibility in experimental design
(Wang et al. 2017; Kim and Kim 2014). Moreover,
recent advances in protein engineering have yielded
switchable Cas9 variants, whose activity can be con-
trolled with spatiotemporal resolution by an external
stimulus (Gangopadhyay et al. 2019; Nihongaki et al.
2018; Richter et al. 2017; Zhou and Deiters 2016), and
we envisage that such variants developed by us (Suzuki
et al. 2018) and others (Zetsche et al. 2015; Davis et al.
2015; Oakes et al. 2016; Liu et al. 2016; Nguyen et al.
2016; Tang et al. 2017; Senturk et al. 2017; Rose et al.
2017; Nihongaki et al. 2015; Hemphill et al. 2015;
Richter et al. 2016; Jain et al. 2016; Zhou et al. 2018)
can benefit clinical development of in vivo gene editing.
In this review, we will first illustrate the molecular
mechanisms of gene editing and provide examples of
Cas9-mediated gene editing in disease models. We will
then compare different means to deliver Cas9 for in vivo
gene therapy. Finally, wewill discuss how switchable Cas9
variants may advance gene therapy in a clinical setting.
Cas9 for gene editing
Endonucleases that generate a double-strand break at the
targeted DNA sequence are indispensable for gene
editing (Cox et al. 2015; Cornu et al. 2017). There have
been many endonucleases discovered to date that can
cause site-specific double-strand breaks, and many have
been developed for the purpose of gene therapy. Such
endonucleases include meganucleases, zinc-finger nu-
cleases, transcriptional activator-like effector nucleases,
and CRISPR/Cas9 (Cox et al. 2015). Among them,
Cas9, found in the Gram-positive bacterium Streptococ-
cus pyogenes (SpCas9), is arguably the most versatile
(Wang et al. 2017). Although its use in precise gene
editing was initially questioned by its relatively high off-
target activity, this issue has been progressively ad-
dressed through different approaches (Wang et al.
2017), including engineering of SpCas9 variants with
negligible non-specific activity (Slaymaker et al. 2016;
Kleinstiver et al. 2016; Hu et al. 2018).
The popularity of SpCas9 originates from its flexibil-
ity in creating DNA double-strand breaks at different
target sequences (Cox et al. 2015). The specificity of
other endonucleases relies on the amino acid sequence
of the DNA-binding domain. Consequently, when a
new DNA target is required, researchers must alter and
engineer the DNA-binding domain of the endonuclease
to achieve specificity to the new target. Clearly, this
process can be labor-intensive and time-consuming, if
not challenging. In stark contrast, the specificity of
SpCas9 can be determined by a single-strand guide
RNA (gRNA) molecule, rather than the protein domain
within the enzyme (Jinek et al. 2012). Accordingly,
DNA double-strand breaks at desired sites can be easily
introduced by the addition of corresponding gRNA
molecules, which are readily achievable using standard
cloning techniques. Specifically, a gRNAmolecule con-
tains two parts: (i) a 20-nucleotide guide sequence that
complements the DNA target and (ii) a structural motif
essential for binding the enzyme SpCas9. At the molec-
ular level (Jiang and Doudna 2017), a ribonucleoprotein
(a complex of SpCas9 and gRNA) is first formed
(Fig. 2a). In order for the complex to bind to the target
DNA (Fig. 2b), the existence of a protospacer adjacent
motif (PAM) upstream of the DNA target sequence in
the genome is essential (Jinek et al. 2012). Guided by
the PAM sequence and complementarity to the DNA
target, the gRNA in the ribonucleoprotein forms a
double-stranded complex with DNA. Consequently,
the target DNA is cleaved by SpCas9 of the ribonucleo-
protein (Fig. 2c), generating a double-strand break
(Jiang and Doudna 2017). For wild-type SpCas9, 5′-
NGG-3′ is the required PAM sequence, but SpCas9
variants that recognize different PAM sequences have
also been generated (Wang et al. 2017; Hu et al. 2018).
Fig. 1 Two stages of precise gene editing involving a recognition of the target DNA by the endonuclease and subsequent cleavage to
generate a double-strand break and b repair of the break by cellular mechanisms
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Therefore, it is theoretically possible to use SpCas9 and
its variants to target nearly any gene. Given the simplic-
ity and versatility, there has been an exponential use of
SpCas9 in in vitro and in vivo genome editing reported
in the literature (Dangi et al. 2018; Nishitani et al. 2019).
Cellular DNA repair mechanisms
When a double-strand DNA break is formed inside a
cell, there are two major repair mechanisms:
homology-directed repair (HDR, Fig. 3a) and non-
homologous end joining (NHEJ, Fig. 3b) (Wyman
and Kanaar 2006). In HDR, a DNA molecule with
identical nucleotide sequence (i.e., homology) to the
two sides of the break is present and used by the cell
as the template to repair the lesion accordingly. This
ensures the repaired DNA molecule will have
identical nucleotide sequence to the template. The
DNA repair template can be of endogenous or ex-
ogenous origin, and an exogenously supplied tem-
plate can be either single- or double-stranded DNA
(Pawelczak et al. 2018). In the case of double-
stranded DNA, it can be a linear fragment or a
circular plasmid (Pawelczak et al. 2018). For gene
editing, it is also possible to supply a template
containing a new gene of novel function to the cell.
On the other hand, during repair by NHEJ, the two
DNA fragments are reconnected without a template.
In this mechanism, accurate repair yielding an iden-
tical sequence to that before the cleavage is the most
prominent outcome (Fig. 3b), although indels (inser-
tion or deletion of nucleotides) can also be produced
at the cleavage site. However, if the double-strand
break is generated by an endonuclease, products of
accurate repair retain the recognition sequence and
a b
c
Fig. 2 Generation of a DNA double-strand break by Cas9 involving a formation of the ribonucleoprotein, b recognition of the target DNA,
and c cleavage of the double-stranded DNA
a b
Fig. 3 Consequences of repairing a double-strand break by the two cellular mechanisms, a homology-directed repair (HDR) and b non-
homologous end joining (NHEJ)
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are readily re-cleaved by the endonuclease, whereas
indel products are not. Therefore, in the absence of a
repair template, indel products will accumulate and
become the predominant consequence over time.
Since indels in exon sequences often lead to a
frameshift with a premature stop codon, the open
reading frame of the gene is disrupted. Subsequent-
ly, mRNA resulting from such a disrupted gene is
either recognized and degraded by the nonsense-
mediated decay pathway, or translated into truncat-
ed, non-functional protein. The overall outcome is
gene silencing, and this mechanism has been com-
monly used for gene knockout (Wyman and Kanaar
2006; Pawelczak et al. 2018).
Generally, in mammalian systems, most DNA repairs
undergo the NHEJ pathway which is active at all stages
of the cell division cycle, whereas the HDR mechanism
is less efficient and restricted to the S and G2 phases
(Wyman and Kanaar 2006; Pawelczak et al. 2018).
Nevertheless, HDR is desired in many scenarios of gene
editing therapy (see below). HDR efficiency can be
increased by controlling the activity of the endonuclease
at the G2 and S phases, administration of small mole-
cules (e.g., cell cycle arrest drugs, or inhibitors of pro-
teins involved in the NHEJ pathway), or optimization of
repair DNA template format (Pawelczak et al. 2018;
Robert et al. 2015; Paulk et al. 2012). However, it is
still technically challenging to achieve close to 100%
HDR efficiency in mammalian models even when tak-
ing these approaches.
Diseases benefitting from in vivo gene editing
As HDR products always have the correct sequence
restored, this can theoretically be used to restore any
genetic disorder. Indeed, most therapeutic gene editing
research thus far relies on HDR to correct diseased
mutations (Cox et al. 2015; Wang et al. 2017; Cornu
et al. 2017; Nishitani et al. 2019; Yin et al. 2014a). For
example, HDR is particularly suitable to correct in-
frame nonsense mutations, or multiple clustered muta-
tions simultaneously. However, the relative inefficiency
of HDR limits its applications to diseases where low-
efficiency editing can still significantly improve gene
function and disease pathology. For example, a small
percentage of gene correction to exhibit functional res-
toration is beneficial to diseases, such as cystic fibrosis
(Schwank et al. 2013; Hodges and Conlon 2019),
Duchenne muscular dystrophy (Duan 2015; Long
et al. 2014, 2016; Bogdanovich et al. 2002),
Huntington’s disease (Kolli et al. 2017; Carroll et al.
2011; Kordasiewicz Holly et al. 2012), retinal dysfunc-
tion (Min et al. 2005; Narfström et al. 2003), severe
combined immunodeficiency (Gaspar et al. 2004), and
tyrosinemia (Yin et al. 2014a, 2016).
The NHEJ mechanism could provide an efficient ther-
apeutic option for single-gene autosomal dominant dis-
orders. Such disorders are caused by mutations of a sole
gene on one of the autosomal (i.e. non-sex) chromo-
somes. Huntington’s disease (Glorioso et al. 2015) and
epidermolysis bullosa simplex (Lewin et al. 2005) are
two such examples. Because patients of these diseases
retain one copy of the wild-type gene, knockout of the
mutated version via NHEJ will infer the recessive wild-
type copy to regain normal protein function. This general
concept of silencing the single disease-causing allele has
been proven to be effective in a number of knockdown
studies by antisense oligonucleotides (Seyhan 2011). Al-
though the use of Cas9 to silence a gene has not been
fully explored (Kolli et al. 2017; Christie et al. 2017;
Bakondi et al. 2016), it is theoretically possible to use
Cas9-mediated knockout to replace antisense oligonucle-
otides for gene silencing.
Alternatively, DNA repair by the NHEJ approach can
be used to restore a gene silenced by certain indels. One-
nucleotide insertion is themost prevalent outcome (> 20%)
of NHEJ (Cradick et al. 2013; Sürün et al. 2018; Chen
et al. 2018a), so this repair mechanism can restore the open
reading frame of genes containing specific indels (i.e.,…,
− 4, − 1, 2, 5,…). Indeed, this concept has been proven in
cellular models of X-linked chronic granulomatosis dis-
ease, where the production of full-length cytochrome b-
245 heavy chain increased by 25% as the result of non-
templated NHEJ repair (Sürün et al. 2018).
NHEJ can also be used to produce a functional pro-
tein by exon skipping, and this approach has been
explored as a new gene therapy in animal models (Long
et al. 2016; Chen et al. 2018b; Amoasii et al. 2018; Xu
et al. 2016; Aartsma-Rus et al. 2017; Turczynski et al.
2016; Touznik et al. 2014). Many mammalian genes
contain several exons that together code for the amino
acid sequence in the final protein product (Fig. 4a). If a
disease-causing mutation or frame shift occurs in a
region not critical for protein function, exon skipping
can be used to produce a shorter, but functional, protein.
This can be achieved by using two gRNA molecules to
direct Cas9 to cut each end of the mutant exon, followed
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by non-templated NHEJ to connect the adjacent DNA,
resulting in removal of the mutant exon (Fig. 4b). Al-
ternatively, exon skipping can be achieved by disrupting
the intron-exon junction (Fig. 4c). Both strategies have
been successfully demonstrated in mouse models of
Duchenne muscular dystrophy (Long et al. 2016; Chen
et al. 2018b; Amoasii et al. 2018; Xu et al. 2016).
Furthermore, exon skipping approaches have already
been investigated in other genetic diseases, including
muscular dystrophy (Aartsma-Rus et al. 2017), dystro-
phic epidermolysis bullosa (Turczynski et al. 2016), and
neuromuscular diseases (Touznik et al. 2014). There-
fore, it is foreseeable that development of Cas9-
mediated exon skipping will be of clinical interest.
Gene editing can involve exploitation of either of the
endogenous cellular repair pathways, and both have
been studied in vivo for genetic mutation correction
(Table 1). A key advantage of HDR is that the entire
section of DNA can be replaced with a corrected se-
quence, restoring the gene to its wild-type sequence.
This contrasts with NHEJ which produces indels that
may restore the open reading frame, induce exon skip-
ping, or lead to gene knockout. While both may result in
resolution of disease phenotype, only HDR can result in
a DNA sequence indistinguishable from the wild-type
sequence. For both repair mechanisms, prediction tools
are available to analyze any target gene. For HDR, the
most promising gRNA sequences for high-efficiency
Cas9 editing can be generated (O’Brien et al. 2018).
The nature of indels resulting from NHEJ can be
predicted using tools which analyze the most like-
ly outcome for a particular nucleotide sequence
(Chen et al. 2018a). These tools can be used with
target gene sequences to select suitable splice sites
that will increase the probability of a preferred
indel, and therefore the desired outcome. However,
as repair via NHEJ is more efficient than that of
HDR (Wyman and Kanaar 2006; Pawelczak et al.
2018), it would be beneficial to employ NHEJ
whenever possible.
a
b c
Fig. 4 Exon skipping byNHEJ to restore an open reading frame. a Protein production from a normal or disease state DNA. b Exon skipping
by cutting out the mutant exon. c Exon skipping by disrupting the intron-exon boundary
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Delivering Cas9 and gRNA for in vivo gene editing
The practicality of in vitro gene editing using Cas9 is
relatively well established (Wang et al. 2017). For gene
therapy, both ex vivo and in vivo methods can be used to
deliver technologies to cells. Ex vivo delivery involves
removing cells or tissues from patients for editing, then
engrafting the edited cells back into the patient. However,
this review limits the discussion to only in vivo editing.
While the potential applications of its in vivo use are
apparent, delivery of Cas9 and gRNA into the target cells
of the patient is the major obstacle (Wang et al. 2017; Yin
et al. 2017; Mout et al. 2017). The required components
can be delivered together or separately as either DNA,
RNA, or ribonucleoprotein through viral or non-viral
approaches. Ideally, components required for gene
editing are only delivered to necessary cells in patients,
although many current approaches lack the required tar-
get specificity. Here, we discuss the features of nucleic
acid delivery by either viral or non-viral vectors as well as
ribonucleoprotein delivery.
Viral vectors are designed to deliver a payload to the
target cells by utilizing the viral infection pathway,
while most of the non-essential viral genome is removed
from the vector. Integration-deficient lentiviruses, ade-
noviruses, and adeno-associated viruses are the most
popular viral vectors for gene therapy due to their non-
integrating nature, eliminating the risks of mutagenesis
and tumorigenicity associated with gene insertion (Yin
et al. 2017; Lukashev and Zamyatnin 2016; Lundstrom
2018). Among them, adeno-associated viruses are par-
ticularly attractive for their low immunogenicity and
broad ability to target specific tissues, including liver,
brain, skeletal, kidney, retina, lung, and vascular tissue
(Mingozzi and High 2011). In comparison, adenoviral
vectors suffer from high immunogenicity, while
lentiviral vectors normally lack tissue specificity (Yin
et al. 2017; Escors and Breckpot 2010). However, the
large size of the SpCas9 gene (4.3 kilobases) poses a
challenge to pack into a single adeno-associated virus
vector along with the required gRNA (Wu et al. 2010;
Senis et al. 2014). One option is to use two vectors, one
encoding SpCas9 and the other encoding the gRNA.
The two vectors will be delivered simultaneously, an
approach requiring efficient co-transduction of the target
cells (Long et al. 2016; Amoasii et al. 2018; Swiech
et al. 2015). Alternatively, the smaller Staphylococcus
aureus Cas9 (3.2 kilobases) can be used, allowing a
single vector to encode both the SaCas9 and gRNA
(Ran et al. 2015). However, viral systems can induce
long-term transgene expression in humans with a single
injection; thus, the potential induction of immunogenic-
ity against Cas9 protein and increase in off-target editing
due to sustained endonuclease expression need to be
taken into consideration (Yin et al. 2017; Fu et al. 2013).
Non-viral delivery methods, such as hydrodynamic
injection and electroporation, have the potential to trans-
fer large genetic payloads with the advantage of a tran-
sient expression pattern (Yin et al. 2014b). Hydrody-
namic injection is the rapid delivery of a large volume of
DNA-containing solution via intravenous injection (Liu
et al. 1999). This has been used to deliver components
required for Cas9-mediated gene editing in mouse (Yin
et al. 2014a; Zhen et al. 2015) and rat models (Bakondi
et al. 2016). However, as a large injection volume (about
10% of the animal’s body weight) is required, hydrody-
namic injection is unlikely to be suitable for human
applications. Alternatively, electroporation, the stimula-
tion of cells via electrical pulse, can also facilitate cel-
lular uptake of foreign components specific to particular
tissue, and its use has also been demonstrated in animal
models (Bakondi et al. 2016; Xu et al. 2016). However,
Table 1 Examples of in vivo genetic engineering to treat genetic diseases
Disease Gene Form of delivery Repair Reference
Tyrosinemia type 1 Fah Hydrodynamic injection HDR (Yin et al. 2016)
Tyrosinemia type 1 Hpd Hydrodynamic injection NHEJ (Pankowicz et al. 2016)
Hyperammonemia OTC Adeno-associated virus HDR (Yang et al. 2016)
Duchenne muscular dystrophy Dmd Germline injection HDR (Long et al. 2014)
Retinitis pigmentosa Rho Electroporation NHEJ (Bakondi et al. 2016)
Huntington’s disease HTT Adeno-associated virus NHEJ (Yang et al. 2017)
Meesmann’s epithelial corneal dystrophy KRT12 Hydrodynamic injection NHEJ (Courtney et al. 2015)
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due to the large amount of cell death induced in the
treatment area by this method, electroporation has yet to
be employed in human clinical trials. In addition, neither
hydrodynamic injection nor electroporation shows cell
specificity.
Ribonucleoprotein, composed of Cas9 and gRNA,
can be directly delivered into cells for genetic modifica-
tion. In comparison to the delivery of DNA or RNA to
generate ribonucleoprotein in vivo, delivery of ribonu-
cleoprotein is appealing as the molecules are immedi-
ately active, resulting in rapid editing (Kim et al. 2014).
This method is also recognized for its limited half-life,
which reduces potential off-target editing (Liang et al.
2015). A major challenge of ribonucleoprotein delivery
is packaging Cas9 protein with gRNA. Cationic lipids
such as RNAiMAX (Zuris et al. 2015) have enabled
gene editing of up to 20% in mouse models and have
entered clinical testing for other gene therapies
(Fitzgerald et al. 2014; Coelho et al. 2013). Gold nano-
particles have also been used to deliver the ribonucleo-
protein in mouse models (Lee et al. 2017a). The nano-
particles were complexed with donor DNA, Cas9 RNP,
and PAsp(DET). PAsp(DET) is a polymer that induces
both endocytosis and later endosomal disruption to re-
lease CRISPR components into the cytosol. Although
target-specific delivery by these means are yet limited to
local injections, recent development of receptor-
mediated ribonucleoprotein delivery has shown cell
specificity in vitro (Rouet et al. 2018), indicating the
possibility of targeted ribonucleoprotein delivery.
Many factors need to be considered when selecting
the delivery vector. An ideal delivery method should
have high specificity to the diseased cells and tissues, be
non-immunogenic and non-toxic to the host, and enable
transient Cas9 activity to minimize potential off-target
editing. Although none of the currently available deliv-
ery methods fulfill all these criteria (Table 2), it is
possible to use a switchable Cas9 variant to control
tissue specificity and the duration of Cas9 activity.
Switchable Cas9
Cas9 variants that can be regulated by an external stim-
ulus are of great interest to therapeutic development, as
they allow an extra level of spatial and temporal control
over gene editing (Gangopadhyay et al. 2019;
Nihongaki et al. 2018; Richter et al. 2017; Zhou and
Deiters 2016). Improved spatial resolution limits Ta
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activity to specific cells and tissues, if this is not already
conferred by the delivery vector, whereas control over
temporal resolution can minimize off-target editing by
confining the duration of active Cas9 in cells (Hu et al.
2018; Yin et al. 2014a). To date, different switchable
Cas9 variants have been developed (Gangopadhyay
et al. 2019; Nihongaki et al. 2018; Richter et al. 2017;
Zhou and Deiters 2016), and their activity can be con-
trolled by temperature (Richter et al. 2016; Jiang et al.
2019), light (Nihongaki et al. 2015; Hemphill et al.
2015; Richter et al. 2016; Jain et al. 2016; Zhou et al.
2018), or small molecules (Suzuki et al. 2018; Zetsche
et al. 2015; Davis et al. 2015; Oakes et al. 2016; Liu
et al. 2016; Nguyen et al. 2016; Tang et al. 2017;
Senturk et al. 2017; Rose et al. 2017). These variants
work well in vitro; however, their applicability for con-
trolling in vivo gene editing is likely to greatly depend
on the nature of the stimuli.
Temperature-sensitive Cas9 variants (Richter et al.
2016; Jiang et al. 2019) are unlikely to be suitable for
controlling gene editing inside a human body. The body
temperature of humans is normally maintained at 37 °C
with minimal fluctuation. It will therefore be challenging
to maintain a target tissue at an alternative temperature for
an extensive period for gene editing to take place. This
holds even for a Cas9 variant which is active at 29 °C
instead of 37 °C (Richter et al. 2016). Conversely, light is
a unique stimulus that offers superior spatial control to
subcellular levels. However, the major drawback of using
light to modulate Cas9 function is the limited tissue
penetrability (Ash et al. 2017), making this approach
unfeasible when targeting internal organs. To date, light-
responsive Cas9 variants can be controlled by either
365 nm (Hemphill et al. 2015; Jain et al. 2016), 470 nm
(Nihongaki et al. 2015; Richter et al. 2016), or 500 nm
(Zhou et al. 2018) wavelength light, which can penetrate
tissues at about 700, 1600, or 2500μmdepth respectively
(Ash et al. 2017). Therefore, their uses may be limited to
skin diseases, such as epidermolysis bullosa simplex
(Lewin et al. 2005), as the depth of the epidermis is within
130 μm (Sandby-Moller et al. 2003).
Small molecules arguably hold the greatest potential
for controlled in vivo activation of Cas9. High temporal
control is achieved by the time of administration and
dosage of the small molecule. Although high spatial
resolution with this approach can only be achieved by
local administration of the modulator molecules (Han
et al. 2017), small molecules can theoretically reach any
tissues within a human body, unlike regulation by
temperature or light. Ideally, a small-molecule Cas9
modulator should have no effects on other proteins or
biomolecules, preventing disturbance of other cellular
processes. Unfortunately, most switchable Cas9 variants
developed to date are responsive to drug molecules,
such as antibiotic rapamycin (Zetsche et al. 2015), es-
trogen receptor modulator 4-hydroxytamoxifen (Davis
et al. 2015; Oakes et al. 2016; Liu et al. 2016; Nguyen
et al. 2016), Bcl-XL inhibitor A-385358 (Rose et al.
2017), and respiratory drug theophylline (Tang et al.
2017). Nevertheless, there are two approaches to control
Cas9 activity by non-drug molecules, Shield-1 (Senturk
et al. 2017), and Lys(Boc) (Suzuki et al. 2018).
Shield-1, a ligand that binds to and stabilizes an
FKBP12-derived destabilizing protein domain, is highly
cell permeable, and has no in vivo toxicity (Banaszynski
et al. 2008). By fusing the destabilizing domain to
SpCas9, the resultant destabilized Cas9 protein variant
was not detectable in the absence of Shield-1 (Fig. 5a).
Upon addition of Shield-1 into the culture media, Cas9
protein was detected within 2 h, whereas subsequent
removal of Shield-1 from the culture media led to de-
pletion of Cas9 protein within 12 h (Senturk et al. 2017).
Lys(Boc) is an economic, non-canonical amino acid
that does not show any observable toxicity to cell lines
and embryos (Suzuki et al. 2018). It can be site-
specifically incorporated into a protein of interest in
mammalian cells using genetic code expansion. In
mammalian cells, proteins composed of 20 canonical
amino acids are produced by ribosome, which employs
aminoacyl-tRNAs to decode the information on mRNA
to generate the corresponding protein. To expand the
genetic code, an orthogonal aminoacyl-tRNA
synthetase/tRNA pair is introduced into the cell. The
orthogonal synthetase specifically acylates the orthogo-
nal tRNAwith a designated non-canonical amino acid,
such as Lys(Boc), to generate the required
aminoacylated tRNA (Nödling et al. 2019). Here, or-
thogonality means that the orthogonal synthetase does
not use any of 20 canonical amino acids nor any of the
endogenous tRNA as substrate, and the non-canonical
amino acid is not a substrate of any of the endogenous
synthetases. The orthogonal tRNA recognizes a blank
codon on the mRNA to direct incorporation of the non-
canonical amino acid into the target protein. Amber stop
codon (UAG) is usually used as the blank codon due to
its rarity among the three stop codons in most organ-
isms. Pyrrolysyl-tRNA synthetase/tRNA pair from the
archaeaMethanosarcina species is an orthogonal pair in
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mammalian cells and can direct Lys(Boc) incorporation
in response to an amber codon (Nödling et al. 2019).
An SpCas9 gene harboring a centrally located amber
codon alongside a pyrrolysyl-tRNA synthetase/tRNA
pair has been successfully used to control gene editing
inmouse embryos (Suzuki et al. 2018). In the absence of
Lys(Boc), truncated and non-functional SpCas9 is ob-
tained (Fig. 5b), whereas supplementation of the non-
canonical amino acid led to production of full-length
and functional SpCas9 protein. This approach enables
heritable Cas9-mediated mammalian genome editing
that is acutely controlled by the economic and readily
available lysine derivative (Suzuki et al. 2018). Howev-
er, amber suppression may interfere with translation of
endogenous genes ending with the amber stop codon. In
addition, the system requires multiple components to be
delivered to the cell and, as previously discussed, vec-
tors capable of delivering a large cargo are limited.
Currently, duration of Cas9 activity in vivo depends
on the delivery methods as described in Table 2. Switch-
able Cas9 variants can offer a solution to long-term
transgene expression and subsequent off-target editing
associated with viral delivery vectors (Yin et al. 2017;
Fu et al. 2013). The great temporal control of switchable
Cas9 variants enables accurate regulation of genetic
modification, circumventing the concerns over extended
activity timeframes associated with delivery of Cas9
DNA. Cas9 variants regulated by Shield-1 (Senturk
et al. 2017) and Lys(Boc) (Suzuki et al. 2018) can be
switched on and off easily by the presence or absence of
the required small molecule, enabling delicate regula-
tion of Cas9 activity and greater tissue specificity
through local administration of the molecule. Despite
the advantages offered by switchable Cas9 variants,
their uses in disease animal models and therapeutic
applications are still very limited. Considerable further
development of these switchable variants is therefore
needed before they can be applied to the clinical setting.
Conclusions
Progress in gene editing techniques have improved rap-
idly in recent years and benefited by the discovery of
CRISPR/Cas9. The versatile and highly specific gene
editing achieved by Cas9 is so far the most promising
approach for correction of genetic diseases. The poten-
tial for many genetic diseases to be resolved in a
a
b
Fig. 5 Regulation of SpCas9 by non-drug molecules. a Stability
of the fusion protein containing SpCas9 and a FKBP12-derived
destabilizing domain can be regulated by Shield-1 so that in the
absence of Shield-1, all fusion proteins are rapidly degraded. b
Genetic code expansion for site-specific non-canonical amino acid
incorporation is used to control the production of full-length,
functional SpCas9
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permanent and heritable fashion by this technology is
clear and may be achievable in the near future especially
for diseases that could benefit from repair by the NHEJ
mechanism. However, significant improvement in HDR
efficiency is required before the power of this repair
mechanism can be fully exploited for the therapeutic
applications. Regardless of the repair mechanism, a
major hindrance of in vivo gene editing thus far has
been the lack of a suitable delivery vector with cell
specificity, while providing transient Cas9 delivery and
low immunogenicity.
Fortunately, switchable Cas9 variants offer solutions
to some of the obstacles. Specifically, the great temporal
control of switchable Cas9 variants enables rapid and
accurate regulation of genetic modification,
circumventing the extended activity timeframe associat-
ed with some means of Cas9 delivery, whereas the
spatial control of switchable Cas9 variants could pro-
vide target specificity if not conferred by delivery vec-
tors. However, detailed in vivo investigations of switch-
able Cas9 variants are required to translate their use into
clinical applications. Unfortunately, protein scientists
working on Cas9 engineering often lack in vivo exper-
tise. Thus, it will be necessary that scientists working on
tool and therapeutic development closely collaborate, so
the true potential of Cas9-mediated gene therapy can be
transformed into clinical settings.
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